Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ('Inspira,' 'Inspira Technologies,' or the 'Company'), a pioneer in innovative life-support and diagnostic technologies, today announced that it has scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations.
Inspira has ramped up strategic production in order to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs.
'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.'
This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor.
The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a regulatory foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the 'SEC'), which is available on the SEC's website at www.sec.gov .
Company Contact
Inspira Technologies – Media Relations
Email: [email protected]
Phone: +972-9-9664485
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
Sanofi (NASDAQ:SNY)'s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant advance in COPD treatment. This decline comes in contrast to a 2% rise in the broader market, suggesting that investors may be focusing on other company initiatives, such as SNY's recent partnership with Stagecoach Performing Arts to raise awareness about Type 1 diabetes. Despite the short-term drop, Sanofi (NASDAQ:SNY)'s long-term performance remains strong. Over the past five years, the company has delivered a total return of 19.59%, outpacing both the French Pharmaceuticals sector and the broader market, which saw declines of 4% and 4.5% respectively in the past year. Analysts remain optimistic about Sanofi (NASDAQ:SNY)'s future, with the current share price at €95.9 and a consensus target of €117.17, an 18.5% potential upside. The company's Projections for 2028 include revenues of €51.2 billion and earnings of €10.2 billion, supported by innovative drug development and efficient operations. While we acknowledge the potential of SNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None.
Yahoo
17 minutes ago
- Yahoo
Cycurion Announces Continued Listing and Trading of its Common Stock and Warrants on NASDAQ
MCLEAN, Va., June 06, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (Nasdaq: CYCU) ('Cycurion' or the 'Company'), a trusted leader in IT cybersecurity solutions and AI, announces continued listing and trading of its shares of common stock and warrants on NASDAQ. On June 5, 2025, the SEC filed a Form 25 notification of removal from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934 regarding the Units previously listed and registered by Western Acquisition Ventures Corp, the predecessor company prior to the business combination with Cycurion. Cycurion's shares of common stock and warrants continue to be listed and traded on The Nasdaq Global Market and The Nasdaq Capital Market under the symbols 'CYCU' and 'CYCUW', respectively. About CycurionBased in McLean, Virginia, Cycurion (Nasdaq: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare and corporate clients with a commitment to securing the digital future. Forward Looking StatementsThis press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the operations and prospective growth of Cycurion's business. Many factors could cause Cycurion's actual results, performance, or achievements to be materially different from any future results, performance, or achievements described in this press release, including words such as 'continue', 'expect', 'intend', 'will', 'hope', 'should', 'would', 'may', 'potential', and other similar expressions. Such factors could include, among others, those detailed in its Registration Statement on Form S-1 and in its Annual Report on Form 10-K, each as filed with the Securities and Exchange Commission (the 'SEC'). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled 'Risk Factors' in those filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and Cycurion does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. Cycurion cannot assure that such statements will prove to be accurate as actual results, and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Investor Contact:CORE IRinvestors@ Media Contact:Phone: (703) 555-0123Email: media@ in to access your portfolio
Yahoo
19 minutes ago
- Yahoo
Down Nearly 60%, Should You Buy the Dip on SoundHound AI?
SoundHound AI is growing rapidly, but it's racking up steep losses. Its growing dependence on acquisitions raises a few red flags. A lot of growth has already been baked into its valuations. 10 stocks we like better than SoundHound AI › SoundHound AI (NASDAQ: SOUN), a developer of artificial intelligence (AI)-powered audio recognition tools, saw its stock close at a record high of $24.23 on Dec. 26, 2024. But since then, its stock has declined nearly 60%. Let's see why this hot stock fizzled out -- and if its pullback represents a buying opportunity for long-term investors. SoundHound AI's namesake app identifies songs by listening to several seconds of recorded audio or a few hummed bars. However, most of its growth is fueled by Houndify, its developer platform, which allows businesses to create their own custom voice recognition tools. Houndify powers voice recognition features in restaurant ordering platforms, smart TVs, connected cars, and other devices. It's an appealing option for companies that don't want to send data to Microsoft, Alphabet's Google, or other tech giants that provide their own data-gathering voice recognition services. SoundHound AI initially attracted a lot of attention for three reasons. First, its revenue surged 47% in 2022, rose another 47% in 2023, and jumped 85% in 2024. Second, the booming AI market drove a stampede of bulls to its AI-driven stock. Lastly, the AI chipmaking bellwether Nvidia (NASDAQ: NVDA) boosted its stake in SoundHound and integrated its voice recognition tools into its Drive platform for connected vehicles. Yet Soundify's stock stumbled for three reasons. First, most of its growth in 2023 and 2024 was driven by acquisitions -- including the restaurant AI company SYNQ3, the online food ordering platform Allset, and the conversational AI company Amelia. That strategy strengthened its position in the restaurant industry, but it also indicated it was running out of room to grow. Second, those acquisitions made it even tougher to break even. Its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) margins came in at negative 73% last year -- which broadly missed its original target of achieving a positive adjusted EBITDA margin by 2024. Lastly, Nvidia liquidated its entire position in SoundHound AI earlier this year. SoundHound ended 2024 with a backlog of $1.2 billion, and it already serves big automakers like Stellantis, quick-serve restaurants like Chipotle, healthcare institutions like MUSC Health, and tech giants like Tencent. Automakers are adding more voice-activated features to their vehicles, restaurants are using more of its AI tools to process their drive-thru and phone orders, and healthcare institutions are processing more patient requests with Amelia's AI chatbots. SoundHound could still have plenty of room to expand. From 2025 to 2035, the global voice agents market could grow at a compound annual growth rate (CAGR) of 34.8%, according to market research firm as more companies replace their human workers with AI-powered voice agents. For 2025, SoundHound expects its revenue to surge 97%. From 2024 to 2027, analysts expect its revenue to rise at a CAGR of 48%, from $85 million to $277 million. They also expect it to finally squeeze out a positive adjusted EBITDA of $5 million in 2027. That outlook seems promising, but a lot of its future growth has already been baked into its valuations. With a market cap of $4.1 billion, it already trades at 25.5 times this year's sales. It's also more than doubled its number of shares since it went public by merging with a special purpose acquisition company (SPAC) just over three years ago, and that dilution will likely continue as it relies on its secondary offerings to raise fresh cash and its stock-based compensation to subsidize its salaries and acquisitions. So while SoundHound AI is still growing rapidly, it hasn't proven that it deserves its premium valuation or that its business model is sustainable. I might nibble on the stock after its recent pullback -- since its core market is still expanding -- but I wouldn't go all in until it meaningfully narrows its losses. Before you buy stock in SoundHound AI, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoundHound AI wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Chipotle Mexican Grill, Microsoft, Nvidia, and Tencent. The Motley Fool recommends Stellantis and recommends the following options: long January 2026 $395 calls on Microsoft, short January 2026 $405 calls on Microsoft, and short June 2025 $55 calls on Chipotle Mexican Grill. The Motley Fool has a disclosure policy. Down Nearly 60%, Should You Buy the Dip on SoundHound AI? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
